Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fast Titration of Quetiapine in Schizophrenia
NCT00254813Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of quetiapine in schizophrenia and schizoaffective disorder (2 arms), sponsored by AstraZeneca. Primary endpoint: Proportion of patients with moderate and severe adverse events. Started Oct 2004; status: completed.
02
Drugs
quetiapine
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00254813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00254813.